Stockscreener 앱 받기
29.71
4.81%
-1.50
시간 외 거래:
29.65
-0.06
-0.20%
Veracyte Inc 주식(VCYT)의 최신 뉴스
Veracyte projects strong Decipher and Afirma growth, targets 22.5% adjusted EBITDA margin for 2025 - MSN
Veracyte, Inc. Just Beat EPS By 260%: Here's What Analysts Think Will Happen Next - simplywall.st
Veracyte, Inc. Just Recorded A 260% EPS Beat: Here's What Analysts Are Forecasting Next - Yahoo Finance
Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up - Zacks Investment Research
Veracyte First Quarter 2025 Earnings: Beats Expectations - Yahoo Finance
Decoding Veracyte Inc (VCYT): A Strategic SWOT Insight - GuruFocus
Veracyte Inc earnings beat by $0.29, revenue topped estimates - Investing.com Nigeria
Veracyte (VCYT) Target Price Lowered by UBS | VCYT Stock News - GuruFocus
What Makes Veracyte (VCYT) a New Buy Stock - Yahoo Finance
Veracyte shares target cut to $41 by Needham, keeps buy rating - Investing.com Nigeria
Veracyte, Inc. (NASDAQ:VCYT) Q1 2025 Earnings Call Transcript - Insider Monkey
UBS Adjusts Price Target for Veracyte (VCYT) Amid Growth Potential | VCYT Stock News - GuruFocus
UBS Cuts Price Target on Veracyte to $42 From $49, Keeps Buy Rating - marketscreener.com
VERACYTE, INC. SEC 10-Q Report - TradingView
Breaking Down Veracyte: 7 Analysts Share Their Views - Benzinga
Veracyte (VCYT) Target Price Lowered by Needham Analyst | VCYT Stock News - GuruFocus
Veracyte: Q1 Earnings Snapshot - Norwalk Hour
Veracyte Inc (VCYT) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and Strategic Expansions - Yahoo Finance
Veracyte Reports Strong Q1 2025 Financial Growth - TipRanks
Veracyte (VCYT) Reports Strong Q1 Growth Driven by Decipher and Afirma - GuruFocus
Veracyte Announces First Quarter 2025 Financial Results - BioSpace
Veracyte Q1 2025 Earnings Call Transcript - MarketBeat
Earnings call transcript: Veracyte Q1 2025 sees strong revenue growth, stock surges - Investing.com Australia
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimat - GuruFocus
Veracyte (VCYT) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability By Investing.com - Investing.com South Africa
Veracyte Q1 2025 slides: 18% revenue growth, transition to profitability - Investing.com Australia
Veracyte (VCYT) Reaffirms 2025 Revenue Outlook Amid Strong Performance | VCYT Stock News - GuruFocus
Veracyte (VCYT) Exceeds Q1 Revenue Projections with Strong Testing Volume Growth | VCYT Stock News - GuruFocus
Veracyte Inc (VCYT) Q1 2025 Earnings: EPS of $0.09 Beats Estimates, Revenue Surges to $114.5 Million - GuruFocus
Earnings Flash (VCYT) VERACYTE INC. Reports Q1 Revenue $114.5M, vs. FactSet Est of $111.3M - marketscreener.com
Breaking Down the Benefits of Clinical Trial Participation in Cancer Care - Curetoday
Veracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate Cancer - BioSpace
Veracyte launches prostate metastatic test - MSN
Crafting an Individual Treatment Plan for Patients With Prostate Cancer - Curetoday
Cathie Wood's Ark Invest Loads Up On Intellia Therapeutics, Offloads Meta Platforms - Benzinga
Veracyte launches metastatic prostate cancer test - Investing.com
Veracyte launches metastatic prostate cancer test By Investing.com - Investing.com South Africa
Veracyte launches prostate metastatic test (VCYT:NASDAQ) - Seeking Alpha
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier Launch | VCYT Stock News - GuruFocus
Veracyte Announces Expanded Availability of Decipher Prostate Te - GuruFocus
Veracyte (VCYT) Boosts Cancer Care with New Genomic Classifier L - GuruFocus
Veracyte Announces Expanded Availability Of Decipher Prostate Test To Patients With Metastatic Prostate Cancer - marketscreener.com
Press Release Distribution & PR Platform - ACCESS Newswire
Veracyte Announces Multiple Abstracts Demonstrating Power of Dec - GuruFocus
Breakthrough Cancer Insights: 18 New Studies Confirm Veracyte Decipher Test's Power in Prostate and Bladder Cancer - Stock Titan
Veracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute’s SEER Specialized Database Release - 01net
0.60%
1.22%
자본화:
|
볼륨(24시간):